Bayer bought Vividion for $1.5 billion upfront last year, saying that the company would boost its ability to develop medicines against targets once considered “undruggable”.
The latest deal extends that effort, with Tavros tasked with using its functional and computational genomics expertise to find targets for tumour therapies that can be hit by either new or repurposed drugs.
Vividion is making an upfront payment of $17.5 million to get the collaboration underway, with the objective of finding four targets that could generate another $430.5 million in future payments tied to preclinical, clinical development, and commercial achievements.
